These findings give a basis for testing MEK inhibitors as treatment in GSD and strengthen the idea for using RAS pathway inhibitors in other complex lymphatic anomalies caused by mutations in the RAS/MAPK pathway. The gene discussed is MAP2K7; the disease is disorder of glycogen metabolism.